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Objective: We have previously shown the capacity of tenascin-C (TN-C) to induce inﬂammatory media-
tors and matrix degradation in vitro in human articular cartilage. The objective of the present study was
to follow TN-C release into knee synovial ﬂuid after acute joint injury or in joint disease, and to correlate
TN-C levels with markers of cartilage matrix degradation and inﬂammation.
Method: Human knee synovial ﬂuid samples (n ¼ 164) were from a cross-sectional convenience cohort.
Diagnostic groups were knee healthy reference, knee anterior cruciate ligament rupture, with or without
concomitant meniscus lesions, isolated knee meniscus injury, acute inﬂammatory arthritis (AIA) and
knee osteoarthritis (OA). TN-C was measured in synovial ﬂuid samples using an enzyme-linked immu-
nosorbent assay (ELISA) and results correlated to other cartilage markers. TN-C release was also moni-
tored in joints of dogs that underwent knee instability surgery.
Results: Statistically signiﬁcantly higher levels of TN-C compared to reference subjects were observed in
the joint ﬂuid of all human disease groups and in the dogs that underwent knee instability surgery.
Statistically signiﬁcant correlations were observed between the TN-C levels in the synovial ﬂuid of the
human patients and the levels of aggrecanase-dependent Ala-Arg-Gly-aggrecan (ARG-aggrecan) frag-
ments and matrix metalloproteinases 1 and 3.
Conclusions: We ﬁnd highly elevated levels of TN-C in human knee joints after injury, AIA or OA that
correlated with markers of cartilage degradation and inﬂammation. TN-C in synovial ﬂuid may serve dual
roles as a marker of joint damage and a stimulant of further joint degradation.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Tenascin-C (TN-C) is a six-armed extracellular matrix glyco-
protein initially discovered at the myotendinous junction1,2. It is
a member of a family of related proteins comprising TN-C, -R, -X,
and -Y1e3. Tenascins have a modular composition with an amino-
terminal oligomerization domain consisting of heptad repeats,
multiple epidermal growth factor (EGF)-like repeats, a variable
number (from 8 to 14) of ﬁbronectin type III modules, and
a carboxyl-terminal ﬁbrinogen-like globular domain4. The heptad
repeat sequences facilitate the formation of hexamers, in whichL.S. Lohmander, Department




s Research Society International. Pform TN-C is deposited in the tissues1,2. It interacts with other
extra-cellular matrix (ECM) molecules such as integrins, collagens,
proteoglycans, heparin, syndecan, and ﬁbronectin. It plays a major
role in cell adhesion, migration, proliferation, and cellular
signaling5. In addition, TN-C acts as an elastic protein that can
stretch to several times its resting length by stretch-induced
unfolding of its ﬁbronectin type III domains6.
TN-C is abundantly expressed in musculoskeletal tissues during
organogenesis and embryogenesis, while its expression is very
restricted in healthy tissues, and reappears as a high molecular
weight splice variant in association with wound healing, inﬂam-
matory processes, or neoplasia7,8. TN-C is associated with the
development of articular cartilage, but decreases markedly during
maturation of chondrocytes9,10, and almost disappears in adult
cartilage11,12. TN-C is highly re-expressed in the cartilage and the
synovium of diseased or injured joints11e15. There is a correlation
between the levels of TN-C in joint ﬂuids and degree of cartilage
degradation16 or radiographic severity of osteoarthritis (OA)17. Itublished by Elsevier Ltd. All rights reserved.
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macrophages and synovial ﬁbroblasts through activation of toll-like
receptor-4 (TLR4)18.
We have shown elevated levels of TN-C in joint ﬂuid in animal
models of joint disease, and demonstrated the capacity of TN-C to
induce inﬂammatory mediators and matrix degradation in vitro in
human joint cartilage19. The objective of the present study was to
determine the levels of TN-C in synovial ﬂuid of patients with joint
injury and joint disease, and to correlate levels of TN-C with
markers of cartilage matrix degradation and inﬂammation in the
same ﬂuids. TN-C levels were also examined in synovial ﬂuids of
a dog model of joint injury.
Methods
Human synovial ﬂuid samples
Human knee synovial ﬂuids (n ¼ 164) were aspirated without
lavage from a cross-sectional convenience cohort with informed
consent and approval of the Lund University Research Ethics
Committee. Diagnosis was made by arthroscopy, radiography,
assessment of joint ﬂuid and clinical examination. Diagnostic
groups were knee healthy references without current or past knee
symptoms or injury (REF), acute inﬂammatory arthritis (AIA)
(pseudogout, pyrophosphate crystal arthritis), knee anterior
cruciate ligament rupture with or without concomitant meniscus
lesions (ACL), isolated knee meniscus lesions (MEN), and knee OA
(Table I). The OA grades of these groups were based on combined
arthroscopic and radiographic data as described20, where grade 1
represents no structural change, 2e5 represent increasing severity
and extent of arthroscopically observed cartilage damage, and 6e10
represent increasing severity of radiographic changes. Patient
availability determined the number of samples within each group,
as well as age and sex distribution within each diagnostic group.
The volume of joint ﬂuid available from each patient allowed only
a limited and variable number of different biomarker assays for
each sample.
Dog knee joint instability model
Instability surgery was performed in 9.6 (9.1e9.9 range) months
old skeletally mature, purpose-bred male cross-bred hounds
(Marshall Farms, New Rose, NY) weighing 19.4 kg (17.1e21.9 kg
range) in Massachusetts and Pearl River Pﬁzer (formerly Wyeth)
Institutional Animal Care and Use Committee (IACUC)-approved
protocols. Dogs were anesthetized with isoﬂurane and pre-
operative radiographs obtained to ensure that no radiographic
joint abnormalities were present before instability induction. Fen-
tanyl patches were applied pre-operatively and kept in place for
3 days to provide sustained post-operative pain relief. Anterior
cruciate ligament (ACLT) is an established instability model of OA
induction in dogs21,22. A 5 cm longitudinal incision was made
laterally in the femoro-tibial joint, and an arthroscopic knife (with
a retrograde blade) used to transect the ACL under directTable I
Details of patients and volunteers that provided synovial ﬂuid samples
REF
n 8
Age, mean (range) 28 (17e42)
% Male 75
OA grade, mean (range) e
Sampling time (weeks) after onset or injury, mean (range) e
REF ¼ knee healthy references; ACL ¼ knee anterior cruciate ligament rupture; MEN ¼ k
published20.visualization. Strict attention was paid to hemostasis. The tran-
section was conﬁrmed by presence of anterior drawer, and copi-
ously ﬂushed with saline. The joint was closed in four layers
(synovium, joint capsule, subcutaneous and skin). Surgery on the
contralateral knee involved sham surgery that consisted of opening
of the joint without ACLT. Dogs had cage rest for 10 days after
surgery. At 1, 3 and 6 months post-surgery, 4e5 animals per time
point were randomly selected and euthanized via acepromazine
sedation and pentobarbital overdose. The knee joint ﬂuids were
aspirated from both ACLT and contralateral sham knees. Cartilage
was harvested for other studies.
TN-C immunoassay
TN-C was measured using TN-C Large enzyme-linked immu-
nosorbent assay (ELISA) (IBL http://www.ibl-japan.co.jp), with
anti-TN-C 19C4MSmonoclonal antibody against the FNIII-C domain
for capture, and horseradish peroxidase (HRP)-conjugated anti-TN-
C 4F10TT mouse monoclonal antibody against the EGF-like domain
for detection. Monoclonal antibody 19C4MS binds an epitope of the
FNIII-C domain and recognizes large TN-C variants, while 4F10TT
binds an epitope from the EGF domain and recognizes both the
small and large TN-C variants. Details of the assay and antibodies
have been published17,19,23. Samples were diluted in phosphate
buffered saline (PBS) before being assayed following the manu-
facturer’s protocol.
Other biomarkers and assays
The human joint ﬂuid samples assayed for TN-C in the present
study were obtained in the course of previous studies, and assay
results for the F-21-epitope of aggrecan, 846 epitope of aggrecan,
cartilage oligomeric matrix protein (COMP), type II collagen cross-
linked C-telopeptide fragments (CTX-II), procollagen II C-propep-
tide (PCIIC), matrix metalloproteinase (MMP) 1, MMP-3, tissue
inhibitor of matrix metalloproteinases 1 (TIMP-1), MMP-1 activity,
and MMP-3 activity were in part published in the course of these
studies24e32. Immunoassays were performed as described for ARG-
neoepitope aggrecan fragments24,25, aggrecan epitopes using the 1-
F-21 and the 846 monoclonal antibodies24,26, COMP, CTX-II, PCIIC,
MMP-1, MMP-3, and TIMP-127e30. Synovial ﬂuid MMP-1 and -3
proteinase activities were assayed as described32.
Statistical methods
Data were analyzed using Sigmaplot 12 and STATA 12.1.
Biomarker concentrations were not normally distributed and were
therefore logarithmically transformed for statistical analysis,
following which values were normally distributed by Shapiroe
Wilk’s test, allowing parametric tests for diagnostic group differ-
ences by one-way analysis of variance (ANOVA) with HolmeSidak
correction for multiple comparisons against the reference group.
The inﬂuence of OA grade, gender, age and sampling time after
injury or onset of symptoms on TN-C concentrations in humanAIA ACL MEN OA
18 57 69 12
68 (30e91) 29 (14e53) 38 (16e70) 69 (39e89)
63 64 85 45
6 (1e9) 2 (1e6) 2 (1e8) 8 (3e9)
29 (0e510) 112 (0e1,115) 130 (0e1,926) 189 (0e481)
nee meniscus injury; and OA ¼ knee osteoarthritis. OA grade 1e10 was assessed as
TN-C Concentration in Synovial Fluid by Time after Joint Injury
Weeks after Joint Injury
















Fig. 2. Box plot of concentrations of TN-C in human synovial ﬂuids from the reference
group (REF, n ¼ 8), and patients with injury to anterior cruciate ligament and/or the
meniscus (ACL and MEN combined, n ¼ 126). Injury groups were signiﬁcantly
increased over the reference group in all four time windows after injury, P < 0.001
(n ¼ 37, 19, 29, and 41, respectively). Horizontal line of box indicates median value, box
25th and 75th percentiles, whiskers 10th and 90th percentiles, and symbols outliers.
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analysis. To explore the inﬂuence of time between injury and
sampling on TN-C concentration in synovial ﬂuids, the diagnostic
groups ACL and MEN were merged, and samples ordered by time
windows as in Fig. 2. Time-related statistical differences were
assessed by ANOVA. Correlations between concentrations of
different synovial ﬂuid biomarkers were determined by Pearson’s
method. The crude mean fold change in TN-C among the patient
groups ACL, AIA, MEN, and OA, vs the mean value of the REF group,
was estimated and statistically tested with logarithmically trans-
formed values using a linear regression model (ANOVA). Adjust-
ment for differences in age and sex was achieved by including these
variables as covariates in the linear model (analysis of covariance,
ANCOVA). The presented results, in terms of fold change and 95%
conﬁdence interval (CI) limits, were re-transformed back to the
original scale. The fulﬁllment of the assumption that the model
residual had a Gaussian distribution assumption was evaluated
graphically using a normal probability plot. The mean fold change
in TN-C among dogs was estimated with 95% CI using logarithmi-
cally transformed within-dog fold change. It was also tested,
against the null hypothesis that ln(fold change) is nil, using the one-
sample t-test. The presented results, in terms of fold change and
95% CI limits, were re-transformed back to the original scale. The
fulﬁllment of the assumption that within-dog TN-C fold change had
a Gaussian distribution was evaluated graphically using a normal
probability plot. Statistical signiﬁcance was set at 0.05.
Results
TN-C levels in human synovial ﬂuids varied widely between
44 and 2,430 ng/ml. Levels of synovial ﬂuid TN-C were statistically
signiﬁcantly higher in all joint disease and injury groups compared
with the REF group (P < 0.001, Fig. 1). Concentrations in the AIA,
ACL, MEN and OA groups were on average fold increased over the
mean reference group value by 10.9 (95% CIs 5.3, 22.5), 5.0 (2.7, 9.1),
3.5 (2.8, 6.4) and 6.2 (2.8, 14.0), respectively. When the inﬂuence on
TN-C levels of age, gender, OA grade and time between synovial
ﬂuid sampling and injury or onset of symptoms was examined forTN-C Concentration in Synovial Fluid by Diagnosis
Diagnosis
















Fig. 1. Box plot of concentrations of TN-C in human synovial ﬂuids from a knee healthy
reference group (REF, n ¼ 8), and patients with AIA (n ¼ 18), rupture of anterior
cruciate ligament with or without concomitant meniscus lesion (ACL, n ¼ 57), isolated
rupture of the meniscus (MEN, n ¼ 69), or knee OA (n ¼ 12). Disease groups were all
signiﬁcantly increased over REF, P < 0.001. Horizontal line of box indicates median
value, box 25th and 75th percentiles, whiskers 10th and 90th percentiles, and symbols
outliers.the full sample set (n ¼ 164), only time between sampling and
injury or onset of symptoms showed a statistically signiﬁcant
relationship with TN-C concentrations in synovial ﬂuid (P ¼ 0.004).
Accordingly, after injury to the anterior cruciate ligament, meniscus
or both, TN-C levels increased markedly in the acute phase, with
a maximum of an almost seven-fold increase over the mean
reference level between 0 and 12 weeks in the ACL group. With
increasing time after joint injury concentrations decreased, but
were statistically signiﬁcantly increased over the REF group at all
time windows studied, even beyond one year after injury
(P < 0.001, Fig. 2).
At 6 months following ACLT surgery, the operated dog joints
showed bothmacroscopic and histological signs of early stage OA in
the ACL-deﬁcient joint (Fig. 3). Similar to the injured human knee
joints, TN-C was also increased at all time points in the synovial
ﬂuid of the knee of the dogs that underwent ACLT surgery when
compared to the ﬂuids of the contralateral sham-operated left knee
(Table II). In parallel with the human ACL or meniscus injured
knees, the dog ACLT knees showed a 68-fold (31.8,146.1) increase of
TN-C at 1 month after ACL transection that declined to around
52- and 49-fold increases at 3 and 6 months after surgery as
compared to the contralateral sham-operated knees.
Synovial ﬂuid levels of TN-C in the human samples were
statistically signiﬁcantly correlated with several biomarkers
proposed to reﬂect joint tissue turnover (Table III). Notably, TN-C
levels were well correlated with levels of aggrecanase-dependent
Ala-Arg-Gly-aggrecan (ARG-aggrecan) fragments and type II
collagen cross-linked C-telopeptides, less well with aggrecan
epitope F-21 (lacking speciﬁcity for aggrecan proteolytic frag-
ments), but not at all with COMP or PCIIC. Further correlations were
noted with the 846 aggrecan epitope, and with protein levels of
MMP-1, MMP-3 and TIMP-1, as well as with activity levels of MMP-
1 and MMP-3 proteinases.
Discussion
We have found highly increased levels of TN-C in joint ﬂuids
following knee injury in humans and in an analogous dog joint
injury model, as well as in samples of joint ﬂuid from patients with
acute joint inﬂammation or OA. The TN-C levels correlated with
Fig. 3. Representative images of the dog medial femoral condyle at 6 months following ACLT surgery. Top panels show macro views, bottom panels histological sections stained
with safranin-O and fast green. Left panels show sham-operated contralateral joint, right panels show ACLT-operated joint.
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tissue degradation and repair.
Our results conﬁrm and markedly extend previous reports on
the presence of TN-C in human synovial ﬂuids from patients with
OA and rheumatoid arthritis16,17,33. We found the highest average
TN-C concentrations in samples from patients with AIA, and note
that following human knee joint injury, levels were seven-fold
increased in the acute injury phase and more than three-fold
increased even at times longer than 1 year after injury, compared
with the reference group. Similar to human joint injury, TN-C levels
in dog synovial ﬂuids were greatly increased shortly after injury,
and remained elevated for at least 6 months following the joint
insult.
Our results are also consistent with previous work showing an
increased expression of TN-C in human and animal OATable II
TN-C protein in dog knee synovial ﬂuid
Species Category n Mean TN-C in ng/ml Range in ng/ml 95%
Dog 1 m ACLT 4 2817.6 518.3e4011.2 1,24
1 m ContL 4 38.7 11.6e65.5 16,
3 m ACLT 5 850.3 639.3e1261.5 632
3 m ContL 5 17.8 8.0e33.9 9, 2
6 m ACLT 5 809.1 693.4e1113.2 658
6 m ContL 5 16.4 15.1e16.8 16,
ACLT, anterior cruciate ligament transection surgery knee; ContL, contralateral sham-oper
animals within a group tested in triplicates.cartilage19,34, and an increased presence of TN-C in damaged and
OA cartilage determined by immunohistochemistry11e14,35,36.
The cell or tissue source of the TN-C in human or dog synovial
ﬂuids in the present study is uncertain, but a local contribution by
chondrocytes and synovial cells of the injured joint is likely, given
that previouswork has documented the production of TN-C by these
cells and in cartilage explants when stimulated by proinﬂammatory
cytokines14,18,19. The most marked expression increases related to
dedifferentiation of chondrocytes were shown for TN-C, type I
collagen and hypoxia-inducible factor 1-alpha (HIF-1a)37. This does
not exclude a systemic contribution to the synovial ﬂuid levels of TN-
C. Large (350 and 240 kD) and small (210 kD) variants of TN-C have
been detected by us and others in human OA synovial ﬂuids17,19,33,
but information on the detailed structure or the mechanism of
release of TN-C and TN-C fragments into synovial ﬂuid is lacking.WeCIs P-value Fold increase over ContL 95% CIs for fold increase
2, 4,394 <0.001 68.1 31.8, 146.1
61
, 1,069 <0.001 52.1 26.6, 102.0
6
, 961 <0.001 48.7 38.7, 61.4
17
ated knee; m,month. Mean TN-C is themean of the average TN-C values for subjects/
Table III
Correlations of different biomarkers with TN-C levels in human synovial ﬂuid
samples
Pearson product moment correlation
coefﬁcient of ln transformed values
P n
ARG-aggrecan 0.462 <0.001 157
F-21 aggrecan 0.251 <0.001 159
846 Aggrecan 0.342 <0.001 149
COMP 0.024 0.841 75
CTX-II 0.516 <0.001 137
PCIIC 0.109 0.204 138
MMP-1 protein 0.513 <0.001 152
MMP-3 protein 0.456 <0.001 156
TIMP-1 protein 0.409 <0.001 158
MMP-1 activity 0.474 <0.001 128
MMP-3 activity 0.458 <0.001 140
ARG-aggrecan, Ala-Arg-Gly-neoepitope of aggrecanase cleaved aggrecan; F-21
aggrecan, F-21 monoconal antibody epitope of aggrecan; 846 aggrecan, 846 epitope
of aggrecan; COMP, cartilage oligomeric matrix protein; CTX-II, type II collagen
cross-linked C-telopeptides; PCIIC, type II collagen C-propeptide; MMP, matrix
metalloproteinase; TIMP, tissue inhibitor of matrix metalloproteinase. Variable
numbers of assay data are a consequence of variable limitations in sample volume.
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abundant in OA cartilage and synovial ﬂuidswhen compared to non-
OA samples; we found fragments of TN-C of molecular weight lower
than 200 kD only in OA cartilage and synovial ﬂuid19. Our ﬁndings in
OA cartilage were later conﬁrmed by the ﬁnding that smaller frag-
ments <200 kD are speciﬁc to diseased tissue and induce aggreca-
nase activity36. These speciﬁc fragments could beMMP generated as
large variants are known to be more susceptible to MMP cleavage
such as MMP-2 and MMP-738. Considering the low content of TN-C
in normal adult articular cartilage, a signiﬁcant part of the marked
increase of TN-C in joint ﬂuid after injury probably represents the
product of an up-regulated TN-C expression by chondrocytes and
synoviocytes. The marked increases of synovial ﬂuid TN-C levels
found both after dog and human joint injury and in human OA are
thus consistent with, and may serve as a marker of a local upregu-
lation of inﬂammation pathways, and possibly a dedifferentiation of
chondrocytes, in these conditions.
The TLR4 is present on human chondrocytes and the TLR4
expression increases with increasing degree of OA cartilage
damage39. Interestingly, it was shown that TN-C is an endogenous
activator of TLR4 and that mice lacking TLR4 are protected from
erosive arthritis in a model of inﬂammatory arthritis18. Recent
evidence further suggests that synovial dendritic cells may be
activated by TN-C, driving IL-17 synthesis in a murine arthritis
model40. Exposure to exogenous TN-C induced expression of
proinﬂammatory cytokines in synovial explants, macrophages and
synoviocytes from individuals with rheumatoid arthritis via acti-
vation of TLR4, and elicited dose-dependent joint inﬂammation in
mice18. Thus, TN-C fulﬁlls the criteria for an endogenous proin-
ﬂammatory molecule generated in damaged tissue (damage-asso-
ciated molecular patterns, DAMPs), which through activation of
TLR4 mediates persistent inﬂammation and tissue destruction18,41.
Consistent with these ﬁndings, recent studies report that TN-C
fragments, but not full-length TN-C, induce expression of
ADAMTS4 and a dose-dependent release of aggrecanase-generated
ARG-aggrecan fragments from the matrix in OA cartilage36.
The ﬁndings brieﬂy summarized here on the role of TN-C
through activation of TLR4, with a focus on inﬂammatory joint
disease, suggest that the high concentrations of TN-C we have
detected being released into human joint ﬂuids after joint injury
and in OA may serve to induce and prolong inﬂammation and
matrix degradation also in these conditions. Activation of TLR
through DAMPs such as TN-C may be particularly relevant in the
acute phase after joint injury. The correlations noted in this studybetween TN-C on the one hand, and aggrecanase-generated
ARG-aggrecan fragments, type II collagen C-telopeptides, and
MMP protein content and protease activity on the other hand, add
further support to this hypothesis.We have in the present study not
demonstrated a direct relationship between TN-C fragment
generation and aggrecanase or MMP activity. However, large vari-
ants of TN-C have been shown to be susceptible to MMP cleavage38,
and human cartilage subjected to digestion with aggrecanase
generates cleaved TN-C peptides that map to the N-terminal
assembly domain, suggesting that the generation of TN-C frag-
ments by proteases may stimulate proteases and in turn a positive
feedback loop of further cartilage matrix degradation42.
Our study has some limitations, notably in the use of a cross-
sectional sample collection of human and canine samples to illus-
trate time-related events after joint injury.We further acknowledge
that validation of the TN-C assay is limited with regard to its
speciﬁcity and the TN-C variants recognized. In the dog study, we
used the contralateral knee of the same animal as a control. The
bias associated with the use of a ‘contralateral control joint’ is
difﬁcult to predict. Firstly, the contralateral control joint may be
systemically affected by the surgical procedure on the index joint,
and may also be affected by changes in joint loading due to the
defective index joint. The resulting bias on any ‘between-sides’
differences are difﬁcult to predict but could serve to decrease
apparent differences between the index and control joints. We have
interpreted biomarker results based on concentrations in synovial
ﬂuid, without consideration of likely variations in synovial ﬂuid and
biomarker clearance between different diagnostic groups and
different disease phases. As clearance increases with joint inﬂam-
mation, biomarker concentrations are confounded with regard to
their relationship with actual joint tissue biomarker release43.
In conclusion, TN-C fragments released into synovial ﬂuid after
joint injury and in OA may serve as a biomarker of inﬂammation
and chondrocyte dedifferentiation, and at the same time act to
induce and prolong inﬂammation in these conditions. However,
intact TN-C in the cartilage appears to have a role in matrix
formation, development and repair, and interacts with the aggre-
can G3 domain9,10,44,45, and deﬁciency of TN-C in knock-out mice is
associated with accelerated development of OA and delayed repair
of cartilage damage46. Further work is needed to fully understand
the consequences of the up-regulated synthesis of TN-C, its frag-
mentation and release into joint ﬂuid after joint injury and in OA.
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